Free tool
FAERS Monitor: Arbli
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218772 or its brand name (Arbli, Losartan Potassium). Reports on generic versions are filed under their own applications.
Reports
52,270
Serious
29,235
56% of reports
Hospitalization
13,706
Death reported
3,177
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue4,330
- diarrhoea3,322
- nausea2,981
- drug ineffective2,899
- dyspnoea2,762
- headache2,690
- dizziness2,520
- pain2,351
- cough2,055
- off label use1,990
- arthralgia1,969
- pruritus1,949
- product dose omission issue1,903
- rash1,799
- asthenia1,752
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 280 |
| 2005 | 365 |
| 2006 | 246 |
| 2007 | 382 |
| 2008 | 479 |
| 2009 | 424 |
| 2010 | 504 |
| 2011 | 1,586 |
| 2012 | 2,177 |
| 2013 | 902 |
| 2014 | 1,101 |
| 2015 | 1,793 |
| 2016 | 2,688 |
| 2017 | 2,976 |
| 2018 | 3,561 |
| 2019 | 3,936 |
| 2020 | 3,608 |
| 2021 | 3,782 |
| 2022 | 3,829 |
| 2023 | 3,922 |
| 2024 | 4,387 |
| 2025 | 5,135 |
| 2026 | 4,206 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,001,889 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| coughSignal | 2,055 | 3.0 | 2.8 | 2,687 |
| product dose omission issueSignal | 1,903 | 2.6 | 2.5 | 1,910 |
| fatigueSignal | 4,330 | 2.2 | 2.2 | 3,085 |
| diarrhoeaSignal | 3,322 | 2.1 | 2.0 | 1,901 |
| pruritusSignal | 1,949 | 2.0 | 2.0 | 1,055 |
| dizzinessSignal | 2,520 | 2.0 | 2.0 | 1,357 |
| dyspnoea | 2,762 | 2.0 | 1.9 | 1,344 |
| arthralgia | 1,969 | 1.9 | 1.8 | 866 |
| asthenia | 1,752 | 1.9 | 1.8 | 729 |
| headache | 2,690 | 1.7 | 1.7 | 849 |
| rash | 1,799 | 1.7 | 1.6 | 483 |
| pain | 2,351 | 1.5 | 1.5 | 459 |
| nausea | 2,981 | 1.5 | 1.5 | 544 |
| off label use | 1,990 | 0.9 | 0.9 | 17 |
| drug ineffective | 2,899 | 0.9 | 0.9 | 46 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.